The identification of CD133+ALDH+ stem-like circulating tumor cells is more promising for studies on tumor biology and prognosis in ovarian cancer than the identification of CTCs by epithelial and mesenchymal marker expression alone. This evidence concerns the gene PROM1 and ovarian carcinoma.